Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 11/2005

01-11-2005 | Review Article

Head-To-Head Comparison of the Costs of Atypical Antipsychotics

A Systematic Review

Authors: Corrado Barbui, Camilla Lintas, Dr Mauro Percudani

Published in: CNS Drugs | Issue 11/2005

Login to get access

Abstract

In many countries, prescribing guidelines recommend the use of atypical or second-generation antipsychotics (SGAs) in the first-line treatment of individuals with newly diagnosed schizophrenia. This recommendation has increased the utilisation of these agents and, consequently, produced a progressive increase in the proportion of total direct costs in schizophrenia accounted for by drug therapy. In this still-evolving context of care, it becomes relevant to critically investigate the literature base on the relative cost effectiveness of each SGA in comparison with the others, the purpose being to ascertain whether the data reveal any one agent to be truly more cost effective than the others.
A systematic search of economic evaluations comparing two or more SGAs yielded 19 studies meeting the inclusion criteria. Of these, 11 were retrospective database or chart review analyses, six were observational prospective or mirror-image studies, and two were randomised clinical trials. Olanzapine and risperidone were compared in 16 studies, two studies compared clozapine, olanzapine and risperidone, and one compared clozapine and risperidone.
While experimental studies indicated an absence of differences among the SGAs in terms of total expenditure, database analyses found contrasting evidence. These latter studies, although susceptible to bias and confounding, should theoretically provide an added dimension, in that they are based on observations from ‘real world’ practice. However, there were too many potential threats to the validity of these analyses to draw a firm conclusion that any one agent is truly more cost effective than the others.
In this uncertain situation, clinicians and policy makers should be aware that indirect evidence from independent randomised controlled trials comparing individual SGAs with haloperidol suggested similar cost effectiveness. As healthcare providers in different settings are ultimately the ones who pay for new innovations, it seems appropriate that they commission research into the cost effectiveness of SGAs.
Literature
1.
Freedman R. Schizophrenia. N Engl J Med 2004; 349: 1738–49
2.
Llorca P-M, Chereau I, Bayle F-J, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129–38PubMedCrossRef
3.
Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1995; 53: 313–9CrossRef
4.
Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacologic basis of therapeutics. New York: McGraw-Hill Press, 2001
5.
Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576–80PubMedCrossRef
6.
Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990–9PubMed
7.
Taylor D, McConnell D, McConnell H, et al. The Maudsley prescribing guidelines. 6th ed. London: Martin Dunitz, 2001
8.
Barbui C, Danese A, Guaiana G, et al. Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 2002; 6: 239–43CrossRef
9.
Kapur S, Remington G. Atypical antipsychotics: patients value the lower incidence of extrapyramidal side effects. BMJ 2000; 321: 1360–1PubMedCrossRef
10.
Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomised controlled trials. Schizophr Res 1999; 35: 51–68PubMedCrossRef
11.
Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6PubMedCrossRef
12.
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6): 553–64PubMedCrossRef
13.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRef
14.
Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219–29PubMedCrossRef
15.
Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17PubMedCrossRef
16.
Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 702–6PubMedCrossRef
17.
EMEA. European Agency for the Evaluation of Medicinal Products public statement on the safety of olanzapine. European Agency for the Evaluation of Medicinal Products 2004, EMEA/CPMP/856/04/Final
18.
Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypothesis for an underlying mechanism. J Am Med Dir Assoc 2004; 5: 129–32PubMedCrossRef
19.
Wooltorton E. Risperidone: increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 26: 1269–70
20.
Wooltorton E. Olanzapine: increased incidence of cerebrovascular events in dementia trials [commentary]. CMAJ 2004; 170: 1395PubMedCrossRef
21.
Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500–8PubMedCrossRef
22.
Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161: 1–56
23.
Mortimer AM. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur Psychiatry 2003; 18: 209–19PubMedCrossRef
24.
25.
Rouillon F, Dansette GY, Le Floch C. Etude de la prise en charge therapeutique des schizophrenes et de son cout. L’Encephale 1994; 20: 303–9PubMed
26.
27.
Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51: 1–18CrossRef
28.
Percudani M, Gerzeli S, Massagrandi R, et al. Costi ed esito dell’assistenza nei soggetti con disturbo mentale grave [Costs and outcome of care in subjects with a severe mental disorder]. Epidemiol Psichiatr Soc 2003; 12: 175–86PubMedCrossRef
29.
Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212–4PubMedCrossRef
30.
Birch S, Gaffni A. Cost-effectiveness and cost-utility analyses: methods for the non-economic evaluation of healthcare programs and how we can do better. In: Geisler E, Heller O, editors. Managing technology in healthcare. Norwell (MA): Kluwer Academic, 1996
31.
Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001; 322: 1596–8PubMedCrossRef
32.
Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalisation in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004; 3: 1–11CrossRef
33.
Byerly MJ, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003; 54: 742–4PubMedCrossRef
34.
Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567–79PubMedCrossRef
35.
Fuller MA, Shermock KM, Secic M, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv 2002; 53: 855–60PubMedCrossRef
36.
Gibson PJ, Damier R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004; 7: 22–35PubMedCrossRef
37.
Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002; 28: 589–605PubMedCrossRef
38.
Kasper S, Jones M, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia: health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 189–96PubMedCrossRef
39.
Kelly DL, Nelson MW, Love RC, et al. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 2001; 52: 676–8PubMedCrossRef
40.
Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62: 749–56PubMedCrossRef
41.
Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 2003; 64: 1293–9PubMedCrossRef
42.
Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998; 20: 1203–17PubMedCrossRef
43.
Rascati KL, Johnsrud MT, Crismond ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21: 683–97PubMedCrossRef
44.
Shermock KM, Sadik MK, Kozma CM, et al. Risperidone, haloperidol and clozapine in the South Carolina Medicaid Program. Dis Manage Health Outcomes 2001; 9: 203–13CrossRef
45.
Snaterse M, Welch R. A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine. Clin Drug Invest 2000; 20: 159–64CrossRef
46.
Taylor DM, Wright T, Libretto SE, et al. Risperidone compared with olanzapine in a naturalistic clinical study: a cost-analysis. J Clin Psychiatry 2003; 64: 589–97PubMedCrossRef
47.
Verma S, Orengo CA, Kunik ME, et al. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int J Geriatr Psychiatry 2001; 16: 223–7PubMedCrossRef
48.
Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six veterans affairs hospitals. Psychiatr Serv 1999; 50: 163–8PubMed
49.
Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002; 15: 75–81PubMed
50.
Zhao Z, Namjoshi M, Barber BL, et al. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine. CNS Drugs 2004; 18(3): 157–64PubMedCrossRef
51.
Kasper S, Rosillon D, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia: efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 179–87PubMedCrossRef
52.
Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editors. Measuring mental health. London: Gaskell, 1992: 163–83
53.
Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. J Clin Psychiatry 1993; 54Suppl. 5: 29–37PubMed
54.
Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
55.
Essock SM, Frisman LK, Covell NH, et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987–94PubMedCrossRef
56.
Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997; 337: 809–15PubMedCrossRef
57.
Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693–702PubMedCrossRef
58.
Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 1999; 60Suppl. 19: 38–45PubMed
Metadata
Title
Head-To-Head Comparison of the Costs of Atypical Antipsychotics
A Systematic Review
Authors
Corrado Barbui
Camilla Lintas
Dr Mauro Percudani
Publication date
01-11-2005
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 11/2005
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200519110-00004

Other articles of this Issue 11/2005

CNS Drugs 11/2005 Go to the issue

Adis Drug Profile

Rotigotine

Leading Article

The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis

Adis Drug Profile

Rotigotine

Review Article

Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders

Review Article

The Use of Triptans in the Management of Menstrual Migraine

Adis Drug Profile

Rotigotine